Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.40 |
| ▸ | EED | O75530 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HLA-A | P04439 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj 2408068 SCHEMBL29427933 | 1.00 | KCNH2 (0.42) | KCNH2NR4A2SSTR5EEDHRH1 | |
| Jnj 2408068 SCHEMBL3890162 | 1.00 | KCNH2 (0.42) | KCNH2NR4A2SSTR5EEDHRH1 | |
| Jnj 2408068 SCHEMBL29365461 | 1.00 | KCNH2 (0.42) | KCNH2NR4A2SSTR5EEDHRH1 | |
| Jnj 2408068 SCHEMBL4980538 | 0.99 | KCNH2 (0.42) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL8287187 | 0.92 | KCNH2 (0.43) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL4776300 | 0.92 | KCNH2 (0.43) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL8289247 | 0.91 | KCNH2 (0.44) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL1495205 | 0.90 | KCNH2 (0.39) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL1495236 | 0.90 | NPY1R (0.42) | KCNH2NR4A2SSTR5EEDHRH1 | |
| SCHEMBL1495235 | 0.88 | KCNH2 (0.39) | KCNH2NR4A2SSTR5EEDHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | KCNH2 4408/4885NR4A2 3764/4885SSTR5 182/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | KCNH2 4408/4885NR4A2 3764/4885SSTR5 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.